- ⚠️《2026年兴奋剂目录》
- 英文名称(5S,8R,9S,10S,13S,14S,17S)-17-Hydroxy-1,10,13-Trimethyl-4,5,6,7,8,9,11,12,14,15,16,17-Dodecahydrocyclopenta[a]Phenanthren-3-One
- 中文名称美替诺龙
- IUPAC名称(5S,8R,9S,10S,13S,14S,17S)-17-hydroxy-1,10,13-trimethyl-4,5,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one
- 其它别名17beta-Hydroxy-1-methyl-5alpha-androst-1-en-3-one; Methenolone
- CAS编号153-00-4
- MFCD编号:MFCD00273128
- EINECS号:205-812-0
- FDA UNII编号:9062ZT8Q5C
- 分子式:C20H30O2分子量:302.46
- 产品CID: 751098
- 产品分类原料药 → 激素及调节内分泌功能类药 → 雄激素及同化激素类药
- 相似结构搜索
- InChIKey: ANJQEDFWRSLVBR-VHUDCFPWSA-N
- 1S/C20H30O2/c1-12-10-14(21)11-13-4-5-15-16-6-7-18(22)19(16,2)9-8-17(15)20(12,13)3/h10,13,15-18,22H,4-9,11H2,1-3H3/t13-,15-,16-,17-,18-,19-,20-/m0/s1
- 计算化学: 氢键受体数2.0氢键供体数1.0可旋转键数*
上下游产品
3-Aethylendioxy-1-methylen-5α-androstanol-(17β)1β-Methyl-4,5α-dihydro-testosteron (17β-Hydroxy-1β-methyl-5α-androstan-3-on) mesterolone atamestane -5α-androst-1-en-3-one17β-acetyloxy-1,4α-dimethyl-2-(phenylthio)methyl-5α-androst-1-en-3-one 📜美替诺龙庚酸酯置于cunninghamella Blakesleeana体系中,用 甲醇 用作溶剂,化学反应 288.0H,反应生成美替诺龙
参考文献:Aspergillus Niger-Mediated Biotransformation Of Methenolone Enanthate,And Immunomodulatory Activity Of Its Transformed Products
标题:Aspergillus Niger-Mediated Biotransformation Of Methenolone Enanthate,And Immunomodulatory Activity Of Its Transformed Products
摘要:Two Fungal Cultures Aspergillus Niger And Cunninghamella Blakesleeana Were Used For The Biotransformation Of Methenolone Enanthate (1). Biotransformation With A. Niger Led To The Synthesis Of Three New (2-4),And Three Known (5-7) Metabolites,While Fermentation With C. Blakesleeana Yielded Metabolite 6. Substrate 1 And The Resulting Metabolites Were Evaluated For Their Immunomodulatory Activities. Substrate 1 Was Found To Be Inactive,While Metabolites 2 And 3 Showed A Potent Inhibition Of Ros Generation By Whole Blood (Ic50= 8.60 And 7.05 Mu G/ml),As Well As From Isolated Polymorphonuclear Leukocytes (Pmns) (Ic50= 14.0 And 4.70 Mu G/ml),Respectively. Moreover,Compound 3 (34.21%) Moderately Inhibited The Production Of Tnf-Alpha,Whereas 2 (88.63%) Showed A Potent Inhibition Of Tnf-Alpha Produced By The Thp-1 Cells. These Activities Indicated Immunomodulatory Potential Of Compounds 2 And 3. All Products Were Found To Be Non-Toxic To 3T3 Mouse Fibroblast Cells. (C) 2016 Elsevier Inc. All Rights Reserved.
Doi:10.1016/j.Steroids.2016.04.007
海关参考信息
- 2901210000-乙烯
2901220000-丙烯
2905122000-异丙醇
2912110000-甲醛 - 💡 提示:海关信息按照顺序优先匹配,如需确认的海关信息,请参考相关资料。
- 详情请参考:📖 海关编码查询和海关进出口税则
专利信息
专利号:US-2013035307-A1
优先权日:2010-01-26
标 题:Methods for treating or preventing the spread of cancer using semi-synthetic glycosaminoglycosan ethers
发明人:PRESTWICH GLENN D; KENNEDY THOMAS P
权利人:UNIV UTAH RES FOUND; PRESTWICH GLENN D; KENNEDY THOMAS P
摘要:Described herein are methods for the treatment and prevention of tumor metastasis using alkylated and fluoroalkylated semi-synthetic glycosaminoglycan ethers (“SAGEsâ€?). The synthesis of sulfated alkylated and fluoroalkylated SAGEs is also described.
专利号:US-2014274978-A1
优先权日:2013-03-15
标题 :Phytosterol spirostane and spirostene derivatives having a wide variety of utilities in humans and other animals
发明人:FASCIOLA ANDRE ARMEL
权利人:FASCIOLA ANDRE ARMEL
摘要:The present invention utilizes phytosterol, phytoecdysteroid, sapogenin, triterpene, terpene, spirostane, spirostene and androstene derivative compounds to provide a wide variety of utilities to humans and other animals. The compounds and methods provide numerous and wide-ranging benefits including biochemical and constructive metabolic benefits including increases in protein synthesis and synthesis efficiency, ergogenic, adaptogenic, cosmetic and medicinal skin agents and veterinary utilities. The compounds provide agents that increase physical endurance and work output, act as a general tonic for increasing health and vigor, increase sleep time and sleep efficiency and act as rejuvenating agents to reverse the effects of fatigue and stress. Novel utilities for pet, farm, zoo and companion animals are also provided.
专利号:US-2025281509-A1
优先权日:2021-04-26
标 题 :Sequential hormone therapy to improve survival and enhance response to immune therapy in men with prostate cancer
发明人:DENMEADE SAMUEL R; ISAACS JOHN T; ANTONARAKIS EMMANUEL S; KACHHAP SUSHANT; MARKOWSKI MARK CHRISTOPHER
权利人:UNIV JOHNS HOPKINS
摘要:Disclosed are methods for treating men with castrate resistant prostate cancer with a sufficient dose of testosterone to achieve supraphysiologic serum levels of testosterone in sequence with androgen ablative treatment or androgen synthesis inhibitors for one or more cycles until evidence of radiographic progression, at which point the subject will receive immune checkpoint blockade therapy.
专利号:US-9023384-B2
优先权日:2004-11-02
标题:Liposome and method for injecting substance to cell using this liposome
发明人:MORITA IKUO; AKIYOSHI KAZUNARI; NOMURA SHINICHIRO
权利人:MORITA IKUO; AKIYOSHI KAZUNARI; NOMURA SHINICHIRO; UNIV TOKYO MEDICAL & DENTAL; DAINIPPON PRINTING CO LTD
摘要:It is intended to efficiently inject into a target cell, a substance charged within a liposome. The present inventors have found that connexin synthesized within a liposome is introduced as connexon having a gap junction function into the liposome membrane. Specifically, the liposome according to the present invention is a liposome in which connexon composed of connexin synthesized by an in-vitro protein synthesis system is incorporated in a state of having a gap junction function.